May 22, 2015— A 340B program proposed regulation establishing civil monetary penalties for drugmakers that intentionally overcharge and setting standards for calculating 340B ceiling prices is penciled in for July, according to the latest edition of the federal government’s regulatory agenda.
Another proposed regulation creating a mandatory and binding 340B administrative dispute resolution process is slated for December. Proposed omnibus 340B program guidance remains on schedule.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)